Mode
Text Size
Log in / Sign up

EMG measurement is feasible in primary care for stable mild to moderate COPD patients.

EMG measurement is feasible in primary care for stable mild to moderate COPD patients.
Photo by Nappy / Unsplash
Key Takeaway
Note that EMG measurement is feasible in primary care but shows limited correlation with breathlessness or HRQoL in stable COPD.

This randomized controlled trial evaluated the feasibility and clinical application of parasternal electromyography (EMG) in patients with chronic obstructive pulmonary disease (COPD). The study population consisted of 40 participants with stable mild to moderate COPD (FEV1 ≥50% predicted) who were already using inhaled corticosteroid therapy. Recruitment occurred across 20 general practices in a primary care setting. Participants were followed for 6 weeks, with measurements taken at baseline, 3 months, and 6 months. The intervention involved the withdrawal of inhaled corticosteroid therapy over 6 weeks, compared to a maintenance group continuing therapy.

High-quality EMG data were successfully obtained from 35 of the 40 participants at baseline and from 31 participants on all three occasions. Intra-rater and inter-rater agreement for EMG measurements was high, with an intraclass correlation coefficient greater than 0.9. Lung function remained stable across the three time points, indicating a consistent study population. Safety and tolerability were not reported, and no adverse events, discontinuations, or serious adverse events were documented in the provided data.

Correlation analyses revealed a moderate negative correlation (r=-0.42, p=0.01) between resting EMG and FEV1% predicted. However, no correlation was observed between resting EMG and participant-reported breathlessness or health-related quality of life (HRQoL) measures. The study limitations include a small sample size and the lack of reported safety data or funding information. The authors note that while an association exists between EMG and airflow obstruction, no causation is implied, and the clinical utility of EMG in stable mild to moderate COPD remains uncertain.

Study Details

Study typeRct
Sample sizen = 35
EvidenceLevel 2
Follow-up1.4 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Neural respiratory drive (NRD) measurement, reflecting the balance between respiratory muscle load and capacity, is quantified using surface parasternal electromyography (EMG). EMG tracks recovery from severe exacerbations of chronic obstructive pulmonary disease (COPD). Among stable COPD participants, we hypothesised the existence of a relationship between NRD, breathlessness and airway obstruction. STUDY AIMS: (1) assessing the feasibility of measuring EMG in COPD participants with forced expiratory volume in 1 s (FEV) ≥50% predicted in primary care; (2) investigating relationships between NRD measures, self-reported breathlessness, airflow obstruction severity and health-related quality of life (HRQoL). METHODS: Participants with stable mild/moderate COPD, using inhaled corticosteroid (ICS) therapy, were recruited from 20 general practices. Participants were randomly allocated to continue using ICS (maintenance group) or to withdraw ICS (withdrawal group) over 6 weeks. EMG, spirometry, self-reported breathlessness (modified Borg dyspnoea scale), COPD Assessment Test and Chronic Respiratory Disease Questionnaire Self-Administered Standardised were measured at baseline, 3- and 6-month follow-up. Bland-Altman plots examined agreement between serial measurements. RESULTS: Forty COPD participants were recruited: age 70±9.2 years; body mass index 26±5.3 kg/m; FEV 1.74±0.54 L; and FEV% pred 69.6±14.0%. High-quality EMG data were obtained from 35 participants at baseline and 31 participants on three occasions. High intra-rater and inter-rater agreement for EMG (intraclass correlation coefficient >0.9) and moderate correlation between EMG and FEV% predicted (r=-0.42; p=0.01) were recorded. No correlation was observed between resting EMG and breathlessness or HRQoL measures across the three time points. CONCLUSIONS: EMG measurement is feasible in primary care. In this group of COPD patients, lung function was stable across the three time points and EMG was associated with the degree of airflow obstruction. In the resting stable state in mild/moderate disease, there was no association between EMG and participant-reported outcomes. Further work should investigate the utility of EMG in mild/moderate COPD participants during acute exacerbation and recovery.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.